Nacev, Benjamin A. http://orcid.org/0000-0003-4991-2492
Dabas, Yakshi
Paul, Matthew R.
Pacheco, Christian
Mitchener, Michelle
Perez, Yekaterina http://orcid.org/0000-0002-6674-4833
Fang, Yan
Soshnev, Alexey A. http://orcid.org/0000-0002-1713-3470
Barrows, Douglas
Carroll, Thomas
Socci, Nicholas D.
St. Jean, Samantha C. http://orcid.org/0000-0001-5555-9299
Tiwari, Sagarika
Gruss, Michael J.
Monette, Sebastien http://orcid.org/0000-0003-2841-6887
Tap, William D.
Garcia, Benjamin A. http://orcid.org/0000-0003-3596-4750
Muir, Tom http://orcid.org/0000-0001-9635-0344
Allis, C. David http://orcid.org/0000-0001-7589-713X
Article History
Received: 19 July 2023
Accepted: 6 June 2024
First Online: 17 June 2024
Competing interests
: W.D.T.: Consulting, Advisory Role, Honoraria: Aadi Biosciences, Abbisko, Amgen, AmMAx Bio, Avacta, Ayala Pharmaceuticals, Bayer, BioAlta, Boehringer Ingelheim, C4 Therapeutics, Cogent Biosciences, Curadev, Daiichi Sankyo, Deciphera, Eli Lilly, Epizyme Inc (Nexus Global Group), Foghorn Therapeutics, Ikena Oncology, IMGT, Inhirbix Inc., Ipsen Pharma, Jansen, Kowa Research Inst., Medpacto, Novo Holdings, PER, Servier, Sonata Therapeutics; research funding from Novartis, Eli Lilly, Plexxikon, Daiichi Sankyo, Tracon Pharma, Blueprint Medicines, Immune Design, BioAlta, Deciphera; Patents, Royalties, Other Intellectual Property: Companion Diagnostics for CDK4 inhibitors (14/854,329), Stock and Other Ownership Interests: Certis Oncology Solution, Atropos. All other authors declare no competing interests. There are no patents related to this manuscript.